Alzamend Neuro, INC 10-Q quarterly reports

Alzamend Neuro reported increased net losses and a 'going concern' warning, despite progress in its AL001 clinical trials and a recent capital raise.

Alzamend Neuro, a clinical-stage biopharmaceutical company, reported a significant increase in net loss for the quarter ended July 31, 2025, while advancing its AL001 clinical program and facing a going concern warning.

Alzamend Neuro announces its financial results for the third quarter of fiscal year 2025, highlighting ongoing clinical trials for AL001 and ALZN002, and recent financing activities to support operations.

Alzamend Neuro's Q2 2024 report shows a decrease in operating expenses and a net loss, while highlighting advancements in clinical trials and recent financing activities.

Alzamend Neuro reported a net loss of $974,411 for the quarter ended July 31, 2024, while advancing clinical trials and securing funding through preferred stock sales.

Alzamend Neuro's Q3 2024 report reveals a net loss of $2.7 million and ongoing efforts to secure additional funding for clinical trials.